Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 43 results.
User Information
Export Records
  1. 1.   Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma
  2. Stauffer,Stacey; Roth, Jacob S; Hernandez, Edjay R; Kowalczyk, Joshua T; Sealover, Nancy E; Hebron,Katie; James,Amy; Isanogle,Kristine; Riffle, Lisa A; Ileva,Lilia; Luo, Xiaoling; Chen, Jin-Qiu; Kedei, Noemi; Kortum, Robert L; Lei, Haiyan; Shern, Jack F; Kalen,Joseph; Edmondson, Elijah F; Hall, Matthew D; Difilippantonio,Simone; Thiele, Carol J; Yohe,Marielle
  3. Cancers. 2024, Jun 25; 16(13):
  1. 2.   Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses
  2. Larkin, Riley M; Lopez, Diana C; Robbins, Yvette L; Lassoued, Wiem; Canubas, Kenneth; Warner,Andrew; Karim,Baktiar; Vulikh, Ksenia; Hodge, James W; Floudas, Charalampos S; Gulley, James L; Gallia, Gary L; Allen, Clint T; London, Nyall R
  3. Journal of Translational Medicine. 2024, May 31; 22(1): 524.
  1. 3.   Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
  2. Sun, Ming; Cao, Yingying; Okada, Reona; Reyes-González, Jeyshka M; Stack, Hannah G; Qin, Haiying; Li, Nan; Seibert,Charlie; Kelly, Michael C; Ruppin, Eytan; Ho, Mitchell; Thiele, Carol J; Nguyen, Rosa
  3. Journal for Immunotherapy of Cancer. 2023, Jan; 11(1):
  1. 4.   Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2)
  2. McReynolds, Lisa J.; Biswas,Kajal; Giri, Neelam; Sharan, Shyam K.; Alter, Blanche P.
  3. Cancer Genetics. 2021, Oct 04; 258-259: 101-109.
  1. 5.   ROR1 and ROR2-novel targets for neuroblastoma
  2. Dave, Hema; Butcher,Donna; Anver, Miriam; Bollard, Catherine M
  3. Pediatric hematology and oncology. 2019, Sep; 36(6): 352-364.
  1. 6.   Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma
  2. Bosse, Kristopher R; Raman, Pichai; Zhu, Zhongyu; Lane, Maria; Martinez, Daniel; Heitzeneder, Sabine; Rathi, Komal S; Kendsersky, Nathan M; Randall, Michael; Donovan, Laura; Morrissy, Sorana; Sussman, Robyn T; Zhelev, Doncho V; Feng, Yang; Wang, Yanping; Hwang, Jennifer; Lopez, Gonzalo; Harenza, Jo Lynne; Wei, Jun S; Pawel, Bruce; Bhatti, Tricia; Santi, Mariarita; Ganguly, Arupa; Khan, Javed; Marra, Marco A; Taylor, Michael D; Dimitrov, Dimiter; Mackall, Crystal L; Maris, John M
  3. Cancer Cell. 2017, Sep 11; 32(3): 295-309.e12.
  1. 7.   Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
  2. Li, Nan; Fu, Haiying; Hewitt, Stephen M; Dimitrov, Dimiter; Ho, Mitchell
  3. Proceedings of the National Academy of Sciences of the United States of America. 2017, Aug 8; 114(32): E6623-E6631.
  1. 8.   Advances in Breast Cancer Therapy Using Nitric Oxide and Nitroxyl Donor Agents
  2. Basudhar, Debashree; Miranda, Katrina M.; Wink, David; Ridnour, Lisa
  3. REDOX-ACTIVE THERAPEUTICS. 2016; : 377-403.
  1. 9.   Analytical characterization of ch14.18 A mouse-human chimeric disialoganglioside-specific therapeutic antibody
  2. Soman, G.; Kallarakal, A. T.; Michiel, D.; Yang, X. Y.; Saptharishi, N.; Jiang, H. G.; Giardina, S.; Gilly, J.; Mitra, G.
  3. Mabs. 2012, Jan-Feb; 4(1): 84-100.
  1. 10.   Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA
  2. Soman, G.; Yang, X. Y.; Jiang, H. G.; Giardina, S.; Mitra, G.
  3. Journal of Immunological Methods. 2011, Oct; 373(1-2): 181-191.
  1. 11.   Systematic Proteome Analysis Identifies Transcription Factor YY1 as a Direct Target of miR-34a
  2. Chen, Q. R.; Yu, L. R.; Tsang, P.; Wei, J. S.; Song, Y. K.; Cheuk, A.; Chung, J. Y.; Hewitt, S. M.; Veenstra, T. D.; Khan, J.
  3. Journal of Proteome Research. 2011, Feb; 10(2): 479-487.
  1. 12.   Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
  2. Shusterman, S.; London, W. B.; Gillies, S. D.; Hank, J. A.; Voss, S. D.; Seeger, R. C.; Reynolds, C. P.; Kimball, J.; Albertini, M. R.; Wagner, B.; Gan, J.; Eickhoff, J.; DeSantes, K. B.; Cohn, S. L.; Hecht, T.; Gadbaw, B.; Reisfeld, R. A.; Maris, J. M.; Sondel, P. M.
  3. Journal of Clinical Oncology. 2010, Nov; 28(33): 4969-4975.
  1. 13.   Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer
  2. Cao, L. A.; Yu, Y. K.; Bilke, S.; Walker, R. L.; Mayeenuddin, L. H.; Azorsa, D. O.; Yang, F.; Pineda, M.; Helman, L. J.; Meltzer, P. S.
  3. Cancer Research. 2010, Aug; 70(16): 6497-6508.
  1. 14.   Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1
  2. Fer, N. D.; Shoemaker, R. H.; Monks, A.
  3. Journal of Experimental & Clinical Cancer Research. 2010, Jul; 29: 7.
  1. 15.   Global Genomic and Proteomic Analysis Identifies Biological Pathways Related to High-Risk Neuroblastoma
  2. Chen, Q. R.; Song, Y. K.; Yu, L. R.; Wei, J. S.; Chung, J. Y.; Hewitt, S. M.; Veenstra, T. D.; Khan, J.
  3. Journal of Proteome Research. 2010, Jan; 9(1): 373-382.
  1. 16.   Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow
  2. Salcedo, R.; Hixon, J. A.; Stauffer, J. K.; Jalah, R.; Brooks, A. D.; Khan, T.; Dai, R. M.; Scheetz, L.; Lincoln, E.; Back, T. C.; Powell, D.; Hurwitz, A. A.; Sayers, T. J.; Kastelein, R.; Pavlakis, G. N.; Felber, B. K.; Trinchieri, G.; Wigginton, J.
  3. Journal of Immunology. 2009 182(7): 4328-4338.
  1. 17.   microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies
  2. Wei, J. S.; Johansson, P.; Chen, Q. R.; Song, Y. K.; Durinck, S.; Wen, X. Y.; Cheuk, A.; Smith, M. A.; Houghton, P.; Morton, C.; Khan, J.
  3. Clinical Cancer Research. 2009 15(17): 5560-5568.
  1. 18.   Brain-derived neurotrophic factor modulates expression of chemokine receptors in the brain
  2. Ahmed, F.; Tessarollo, L.; Thiele, C.; Mocchetti, I.
  3. Brain Research. 2008 1227: 1-11.
  1. 19.   An integrated cross-platform prognosis study on neuroblastoma patients
  2. Chen, Q. R.; Song, Y. K.; Wei, J. S.; Bilke, S.; Asgharzadeh, S.; Seeger, R. C.; Khan, J.
  3. Genomics. 2008 92(4): 195-203.
  1. 20.   Recombinant Oncolytic Poliovirus Eliminates Glioma In Vivo Without Genetic Adaptation to a Pathogenic Phenotype
  2. Dobrikova, E. Y.; Broadt, T.; Poiley-Nelson, J.; Yang, X. Y.; Soman, G.; Giardina, S.; Harris, R.; Gromeier, M.
  3. Molecular Therapy. 2008 16(11): 1865-1872.
  1. 21.   Increased WSB1 copy number correlates with its over-expression which associates with increased survival in neuroblastoma
  2. Chen, Q. R.; Bilke, S.; Wei, J. S.; Greer, B. T.; Steinberg, S. M.; Westermann, F.; Schwab, M.; Khan, J.
  3. Genes Chromosomes & Cancer. 2006, Sep; 45(9): 856-862.
  1. 22.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 23.   Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma
  2. Khan, T.; Hixon, J. A.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Brenner, J.; Lockett, S.; Nagashima, K.; Powell, D.; Wigginton, J. M.
  3. Journal of the National Cancer Institute. 2006, FEB 1; 98(3): 190-202.
  1. 24.   Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors
  2. Stauffer, J. K.; Khan, T.; Salcedo, R.; Hixon, J. A.; Lincoln, E.; Back, T. C.; Wigginton, J. M.
  3. Journal of Immunotherapy. 2006, MAR-APR; 29(2): 151-164.
  1. 25.   Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-4
  2. Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Hamel, E.; Schmidt, J. M.; Pettitt, R. K.
  3. Journal of Medicinal Chemistry. 2005, JUN 16; 48(12): 4087-4099.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel